Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. / Buus, Søren; Claesson, Mogens Helweg.

I: Current Opinion in Immunology, Bind 16, Nr. 2, 2004, s. 137-42.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Buus, S & Claesson, MH 2004, 'Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA', Current Opinion in Immunology, bind 16, nr. 2, s. 137-42. https://doi.org/10.1016/j.coi.2004.02.004

APA

Buus, S., & Claesson, M. H. (2004). Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. Current Opinion in Immunology, 16(2), 137-42. https://doi.org/10.1016/j.coi.2004.02.004

Vancouver

Buus S, Claesson MH. Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. Current Opinion in Immunology. 2004;16(2):137-42. https://doi.org/10.1016/j.coi.2004.02.004

Author

Buus, Søren ; Claesson, Mogens Helweg. / Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. I: Current Opinion in Immunology. 2004 ; Bind 16, Nr. 2. s. 137-42.

Bibtex

@article{c0f4c210ebca11ddbf70000ea68e967b,

title = "Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA",

abstract = "The rationale of a T-cell epitope-based approach to cancer treatment is primarily rooted in the hypothesis that CD8(+) cytotoxic T cells (CTLs) can be manipulated to specifically identify and kill cancer cells. A solid understanding of CTL specificity and activation is a fundamental requirement for tumor immunotherapy. The means to identify tumor-specific CTL epitopes and to monitor corresponding CTL responses are important enabling technologies. Recent advances in these enabling technologies include their ability to exploit genomic, transcriptomic and proteomic information. These advances constitute new opportunities, which will enable approaches to tumor immunotherapy that encompass both human diversity and tumor heterogeneity, increase the efficacy of tumor immunotherapy and potentially provide the opportunity for individualized therapy.",

author = "S{\o}ren Buus and Claesson, {Mogens Helweg}",

note = "Keywords: Epitopes, T-Lymphocyte; Humans; Immunotherapy; Major Histocompatibility Complex; RNA, Messenger; T-Lymphocytes, Cytotoxic",

year = "2004",

doi = "10.1016/j.coi.2004.02.004",

language = "English",

volume = "16",

pages = "137--42",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Ltd. * Current Opinion Journals",

number = "2",

}

RIS

TY - JOUR

T1 - Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA

AU - Buus, Søren

AU - Claesson, Mogens Helweg

N1 - Keywords: Epitopes, T-Lymphocyte; Humans; Immunotherapy; Major Histocompatibility Complex; RNA, Messenger; T-Lymphocytes, Cytotoxic

PY - 2004

Y1 - 2004

N2 - The rationale of a T-cell epitope-based approach to cancer treatment is primarily rooted in the hypothesis that CD8(+) cytotoxic T cells (CTLs) can be manipulated to specifically identify and kill cancer cells. A solid understanding of CTL specificity and activation is a fundamental requirement for tumor immunotherapy. The means to identify tumor-specific CTL epitopes and to monitor corresponding CTL responses are important enabling technologies. Recent advances in these enabling technologies include their ability to exploit genomic, transcriptomic and proteomic information. These advances constitute new opportunities, which will enable approaches to tumor immunotherapy that encompass both human diversity and tumor heterogeneity, increase the efficacy of tumor immunotherapy and potentially provide the opportunity for individualized therapy.

AB - The rationale of a T-cell epitope-based approach to cancer treatment is primarily rooted in the hypothesis that CD8(+) cytotoxic T cells (CTLs) can be manipulated to specifically identify and kill cancer cells. A solid understanding of CTL specificity and activation is a fundamental requirement for tumor immunotherapy. The means to identify tumor-specific CTL epitopes and to monitor corresponding CTL responses are important enabling technologies. Recent advances in these enabling technologies include their ability to exploit genomic, transcriptomic and proteomic information. These advances constitute new opportunities, which will enable approaches to tumor immunotherapy that encompass both human diversity and tumor heterogeneity, increase the efficacy of tumor immunotherapy and potentially provide the opportunity for individualized therapy.

U2 - 10.1016/j.coi.2004.02.004

DO - 10.1016/j.coi.2004.02.004

M3 - Journal article

C2 - 15023404

VL - 16

SP - 137

EP - 142

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 2

ER -

ID: 9943364